LCTXLineage Cell Therapeutics Inc
Slide 1 of 3
Company Overview
Name
Lineage Cell Therapeutics Inc
52W High
$2.09
52W Low
$0.37
Market Cap
$393.9M
Dividend Yield
0%
Price/earnings
-0.13
P/E
-0.13
Dividends
No dividend
Sentiment
Score
Mixed
50
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Slide 2 of 3
Income Statement
Total Revenue
$3.7M
Operating Revenue
$3.7M
Total Gross Profit
$3.7M
Total Operating Income
$-3.8M
Net Income
$-29.8M
EV to EBITDA
$0.00
EV to Revenue
$32.56
Price to Book value
$17.87
Price to Earnings
$0.00
Additional Data
Selling, General & Admin Expense
$4.2M
Research & Development Expense
$3.3M
Impairment Charge
N/A
Total Operating Expenses
$-7.5M
Interest & Investment Income
$366K
Other Income / (Expense), net
$-26.3M
Slide 3 of 3
Earnings History
Estimated EPS
Reported EPS
N/A Slide 1 of 5
Company Overview
Name
Lineage Cell Therapeutics Inc
52W High
$2.09
52W Low
$0.37
Market Cap
$393.9M
Dividend Yield
0%
Price/earnings
-0.13
P/E
-0.13
Dividends
No dividend
Slide 2 of 5
Sentiment
Score
Mixed
50
Low
Neutral
High
0
50
100
Trade Volume
Score
Neutral
50
Low
Neutral
High
0
50
100
Slide 3 of 5
Income Statement
Total Revenue
$3.7M
Operating Revenue
$3.7M
Total Gross Profit
$3.7M
Total Operating Income
$-3.8M
Net Income
$-29.8M
EV to EBITDA
$0.00
EV to Revenue
$32.56
Price to Book value
$17.87
Price to Earnings
$0.00
Slide 4 of 5
Additional Data
Selling, General & Admin Expense
$4.2M
Research & Development Expense
$3.3M
Impairment Charge
N/A
Total Operating Expenses
$-7.5M
Interest & Investment Income
$366K
Other Income / (Expense), net
$-26.3M
Slide 5 of 5
Earnings History
Estimated EPS
Reported EPS
N/AUpcoming Earnings
We were not able to find an announced earnings date for this symbol yet. Check back again later
Company Info
CEO
Brian M. Culley
Location
California, USA
Exchange
NYSE
Website
https://lineagecell.com
Summary
OpRegen, a retinal pigment epithelium cell replacement therapy, is in Phase I/IIa clinical trial for the treatment of dry age-related macular degeneration.
Company Info
CEO
Brian M. Culley
Location
California, USA
Exchange
NYSE
Website
https://lineagecell.com
Summary
OpRegen, a retinal pigment epithelium cell replacement therapy, is in Phase I/IIa clinical trial for the treatment of dry age-related macular degeneration.
